MRI Hippocampus Differential Response to Donepezil vs Placebo in Mild Cognitive Impairment and Alzheimer’s Disease: A Systematic Review of Four Randomized Clinical Trials

Youssef A. Ismail, Youssef Haitham, Mohammad Walid, Hazim Mohamed, Youssef M. Abd El‐Satar · 2025

Read MRI Hippocampus Differential Response to Donepezil vs Placebo in Mild Cognitive Impairment and Alzheimer’s Disease: A Systematic Review of Four Randomized Clinical Trials by Youssef A. Ismail, Youssef Haitham, Mohammad Walid, Hazim Mohamed, Youssef M. Abd El‐Satar (2025) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-11713534.txt.

Description

Youssef Ismail and co-authors review four clinical trials of the drug donepezil in this 2025 paper. Donepezil is a standard drug for Alzheimer's disease and mild memory impairment. The authors ask whether the drug slows shrinking of the hippocampus, a brain area key to memory.

The team searched major medical databases and kept only trials that compared the drug with a placebo using brain scans. Four trials qualified, with five hundred ninety-nine people in total, followed for twelve months. The review weighs whether scan results show a real edge for the drug. Such evidence helps doctors judge what the medicine can and cannot do.

Catalog record

CREATORYoussef A. Ismail, Youssef Haitham, Mohammad Walid, Hazim Mohamed, Youssef M. Abd El‐Satar
YEAR2025
COLLECTIONPAPERS
FORMATTXT
FILE SIZE2 KB
VERSION1.0
LICENSECC BY 4.0
RIGHTSCC BY
SOURCEEurope PMC

Source: https://europepmc.org/articles/PMC11713534

Browse the full library · About the Tower of Babel